Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SACUBITRIL AND VALSARTAN TABLETS safely and effectively. See full prescribing information for SACUBITRIL AND VALSARTAN TABLETS. SACUBITRIL AND VALSARTAN tablets, for oral use Initial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)]. Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and are expected to improve cardiovascular outcomes.
- generic_name
- sacubitril and valsartan
- product_names
- Sacubitril and Valsartan
- ndc
- 70954-975, 70954-975-20, 70954-975-30, 70954-975-50, 70954-976, 70954-976-20, 70954-976-30, 70954-976-50, 70954-977, 70954-977-20, 70954-977-30, 70954-977-50
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en